Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Рациональные подходы к лечению кашля
Рациональные подходы к лечению кашля
Кучмин А.Н., Евсюков К.Б., Шуленин С.Н., Шевелев А.А. Рациональные подходы к лечению кашля. Болезни органов дыхания (Прил. к журн. Consilium Medicum). 2019; с. 50–54. DOI: 10.26442/26190079.2019.190594
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Кашель является наиболее распространенным симптомом поражения органов дыхания. Курация пациентов с кашлем предполагает комплексное обследование с целью постановки диагноза и назначение этиотропного лечения. Выбор того или иного противокашлевого лечения должен определяться анализом особенностей кашля, течением острой и наличием хронической бронхолегочной патологии. В случае необходимости лечения кашля целесообразно использовать препараты с доказанной клинической эффективностью.
Ключевые слова: кашель, мокрота, фармакотерапия кашля, мукоактивная терапия, препараты, подавляющие кашель, муколитики, ацетилцистеин, амброксол.
Key words: cough, sputum, cough pharmacotherapy, mucoactive therapy, cough suppressant drugs, mucolytics, acetylcyteine, ambroxol.
Ключевые слова: кашель, мокрота, фармакотерапия кашля, мукоактивная терапия, препараты, подавляющие кашель, муколитики, ацетилцистеин, амброксол.
________________________________________________
Key words: cough, sputum, cough pharmacotherapy, mucoactive therapy, cough suppressant drugs, mucolytics, acetylcyteine, ambroxol.
Полный текст
Список литературы
1. Зайцев А.А. Современный взгляд на фармакотерапию кашля. Практическая пульмонология. 2018; 3: 88–94.
[Zaitsev A.A. Sovremennyi vzgliad na farmakoterapiiu kashlia. Prakticheskaia pul'monologiia. 2018; 3: 88–94 (in Russian).]
2. Чучалин А.Г., Амбросимов В.Н. Кашель. Мoscow: Эхо, 2012.
[Chuchalin A.G., Ambrosimov V.N. Kashel'. M.: Ekho, 2012 (in Russian).]
3. Morice A. Epidemiology of cough. Pulm Pharmacol Ther 2002; 15: 253–9.
4. Burt CW, Schappert SM. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1999–2000. Vital Health Stat 2004; 157: 1–70.
5. Cerveri I, Accordini S, Corsico A et al. Chronic cough and phlegm in young adults. Eur Respir J 2003; 22 (3): 413–7.
6. Cullinan P. Persistent cough and sputum: prevalence and clinical characteristics in south east England. Respir Med 1992; 86: 143–9.
7. Lundback B, Nystrom L, Rosenhall L et al. Obstructive lung disease in northern Sweden: respiratory symptoms assessed in a postal survey. Eur Respir J 1991; 4: 257–66.
8. Cough. Understanding and treating a problem with many causes. Am College Chest Physicians 2000.
9. Бердникова Н.Г., Цыганко Д.В., Демидова Г.В. Особенности применения ацетилцистеина в клинической практике. РМЖ. 2008; 16 (2): 78–82.
[Berdnikova N.G., Tsyganko D.V., Demidova G.V. Osobennosti primeneniia atsetiltsisteina v klinicheskoi praktike. RMZh. 2008; 16 (2): 78–82 (in Russian).]
10. Lindner Н, Holier Е, Erd В. Peripheral blood mononuclear cells induce programmed cell death in human endothelial cells and mav prevent repair: role of cytokines. Blood 1997; 89 (6): 1931–8.
11. Вотчал Б.Е. Очерки клинической фармакологии. М., 1965; с. 428–33.
[Votchal B.E. Ocherki klinicheskoi farmakologii. M., 1965; s. 428–33 (in Russian).]
12. Резников А.М., Марченков Я.В. Хронический персистирующий кашель. Атмосфера. Пульмонология и аллергология. 2002; 4: 40–1.
[Reznikov A.M., Marchenkov Ia.V. Khronicheskii persistiruiushchii kashel'. Atmosfera. Pul'monologiia i allergologiia. 2002; 4: 40–1 (in Russian).]
13. Зайцев А.А., Оковитый С.В., Крюков Е.В. Кашель. Практическое пособие для врачей. М., 2015.
[Zaitsev A.A., Okovityi S.V., Kriukov E.V. Kashel'. Prakticheskoe posobie dlia vrachei. Мoscow, 2015 (in Russian).]
14. Albert RH. Diagnosis and treatment of acute bronchitis. Am Fam Physician 2010; 82: 1345–50.
15. Оковитый С.В., Анисимова Н.А. Фармакологические подходы к противокашлевой терапии. Рус. мед. журн. 2011 (23): 1150–8.
[Okovityi S.V., Anisimova N.A. Farmakologicheskie podkhody k protivokashlevoi terapii. Rus. med. zhurn. 2011 (23): 1150–8 (in Russian).]
16. Зайцев А.А. Мукоактивная терапия кашля: что за горизонтом? Лечащий врач. 2018; 10: 22–6.
[Zaitsev A.A. Mukoaktivnaia terapiia kashlia: chto za gorizontom? Lechashchii vrach. 2018; 10: 22–6 (in Russian).]
17. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2011; 322 (7297).
18. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005; 25 (3): 552–63.
19. Ekberg-Jansson A, Larsson S, Lofdahl C-G. Preventing exacerbations of chronic bronchitis and COPD. Two recent Cochrane reviews report effective regimens. BMJ 2001; 322: 7297.
20. Beeh KM, Beier J, Esperester A, Paul LD. Antiinflammatory properties of ambroxol. Eur J Med Res 2008; 13: 12: 557–62.
21. Балясинская Г.Л., Богомильский М.Р., Люманова С.Р., Волков И.К. Применение Флуимуцила (N-ацетилцистеина) при заболеваниях легких. Педиатрия. 2005; 6.
[Baliasinskaia G.L., Bogomil'skii M.R., Liumanova S.R., Volkov I.K. Primenenie Fluimutsila (N-atsetiltsisteina) pri zabolevaniiakh legkikh. Pediatriia. 2005; 6 (in Russian).]
22. Cazzola M, Calzetta L, Page C et al. Influence of Nacetylcysteine on chronic bronchitis or COPD exacerbations: a metaanalysis. Eur Respir Rev 2015; 24 (137): 451–61.
23. Stey C et al. The effect of oral N-Acetylcysteine in chronic bronchitis: a guantitative systematic review. Eur Respir J 2000; 16: 253–62.
2. Chuchalin A.G., Ambrosimov V.N. Kashel'. M.: Ekho, 2012 (in Russian).
3. Morice A. Epidemiology of cough. Pulm Pharmacol Ther 2002; 15: 253–9.
4. Burt CW, Schappert SM. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1999–2000. Vital Health Stat 2004; 157: 1–70.
5. Cerveri I, Accordini S, Corsico A et al. Chronic cough and phlegm in young adults. Eur Respir J 2003; 22 (3): 413–7.
6. Cullinan P. Persistent cough and sputum: prevalence and clinical characteristics in south east England. Respir Med 1992; 86: 143–9.
7. Lundback B, Nystrom L, Rosenhall L et al. Obstructive lung disease in northern Sweden: respiratory symptoms assessed in a postal survey. Eur Respir J 1991; 4: 257–66.
8. Cough. Understanding and treating a problem with many causes. Am College Chest Physicians 2000.
9. Berdnikova N.G., Tsyganko D.V., Demidova G.V. Osobennosti primeneniia atsetiltsisteina v klinicheskoi praktike. RMZh. 2008; 16 (2): 78–82 (in Russian).
10. Lindner Н, Holier Е, Erd В. Peripheral blood mononuclear cells induce programmed cell death in human endothelial cells and mav prevent repair: role of cytokines. Blood 1997; 89 (6): 1931–8.
11. Votchal B.E. Ocherki klinicheskoi farmakologii. M., 1965; s. 428–33 (in Russian).
12. Reznikov A.M., Marchenkov Ia.V. Khronicheskii persistiruiushchii kashel'. Atmosfera. Pul'monologiia i allergologiia. 2002; 4: 40–1 (in Russian).
13. Zaitsev A.A., Okovityi S.V., Kriukov E.V. Kashel'. Prakticheskoe posobie dlia vrachei. Мoscow, 2015 (in Russian).
14. Albert RH. Diagnosis and treatment of acute bronchitis. Am Fam Physician 2010; 82: 1345–50.
15. Okovityi S.V., Anisimova N.A. Farmakologicheskie podkhody k protivokashlevoi terapii. Rus. med. zhurn. 2011 (23): 1150–8 (in Russian).
16. Zaitsev A.A. Mukoaktivnaia terapiia kashlia: chto za gorizontom? Lechashchii vrach. 2018; 10: 22–6 (in Russian).
17. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2011; 322 (7297).
18. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005; 25 (3): 552–63.
19. Ekberg-Jansson A, Larsson S, Lofdahl C-G. Preventing exacerbations of chronic bronchitis and COPD. Two recent Cochrane reviews report effective regimens. BMJ 2001; 322: 7297.
20. Beeh KM, Beier J, Esperester A, Paul LD. Antiinflammatory properties of ambroxol. Eur J Med Res 2008; 13: 12: 557–62.
21. Baliasinskaia G.L., Bogomil'skii M.R., Liumanova S.R., Volkov I.K. Primenenie Fluimutsila (N-atsetiltsisteina) pri zabolevaniiakh legkikh. Pediatriia. 2005; 6 (in Russian).
22. Cazzola M, Calzetta L, Page C et al. Influence of Nacetylcysteine on chronic bronchitis or COPD exacerbations: a metaanalysis. Eur Respir Rev 2015; 24 (137): 451–61.
23. Stey C et al. The effect of oral N-Acetylcysteine in chronic bronchitis: a guantitative systematic review. Eur Respir J 2000; 16: 253–62.
[Zaitsev A.A. Sovremennyi vzgliad na farmakoterapiiu kashlia. Prakticheskaia pul'monologiia. 2018; 3: 88–94 (in Russian).]
2. Чучалин А.Г., Амбросимов В.Н. Кашель. Мoscow: Эхо, 2012.
[Chuchalin A.G., Ambrosimov V.N. Kashel'. M.: Ekho, 2012 (in Russian).]
3. Morice A. Epidemiology of cough. Pulm Pharmacol Ther 2002; 15: 253–9.
4. Burt CW, Schappert SM. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1999–2000. Vital Health Stat 2004; 157: 1–70.
5. Cerveri I, Accordini S, Corsico A et al. Chronic cough and phlegm in young adults. Eur Respir J 2003; 22 (3): 413–7.
6. Cullinan P. Persistent cough and sputum: prevalence and clinical characteristics in south east England. Respir Med 1992; 86: 143–9.
7. Lundback B, Nystrom L, Rosenhall L et al. Obstructive lung disease in northern Sweden: respiratory symptoms assessed in a postal survey. Eur Respir J 1991; 4: 257–66.
8. Cough. Understanding and treating a problem with many causes. Am College Chest Physicians 2000.
9. Бердникова Н.Г., Цыганко Д.В., Демидова Г.В. Особенности применения ацетилцистеина в клинической практике. РМЖ. 2008; 16 (2): 78–82.
[Berdnikova N.G., Tsyganko D.V., Demidova G.V. Osobennosti primeneniia atsetiltsisteina v klinicheskoi praktike. RMZh. 2008; 16 (2): 78–82 (in Russian).]
10. Lindner Н, Holier Е, Erd В. Peripheral blood mononuclear cells induce programmed cell death in human endothelial cells and mav prevent repair: role of cytokines. Blood 1997; 89 (6): 1931–8.
11. Вотчал Б.Е. Очерки клинической фармакологии. М., 1965; с. 428–33.
[Votchal B.E. Ocherki klinicheskoi farmakologii. M., 1965; s. 428–33 (in Russian).]
12. Резников А.М., Марченков Я.В. Хронический персистирующий кашель. Атмосфера. Пульмонология и аллергология. 2002; 4: 40–1.
[Reznikov A.M., Marchenkov Ia.V. Khronicheskii persistiruiushchii kashel'. Atmosfera. Pul'monologiia i allergologiia. 2002; 4: 40–1 (in Russian).]
13. Зайцев А.А., Оковитый С.В., Крюков Е.В. Кашель. Практическое пособие для врачей. М., 2015.
[Zaitsev A.A., Okovityi S.V., Kriukov E.V. Kashel'. Prakticheskoe posobie dlia vrachei. Мoscow, 2015 (in Russian).]
14. Albert RH. Diagnosis and treatment of acute bronchitis. Am Fam Physician 2010; 82: 1345–50.
15. Оковитый С.В., Анисимова Н.А. Фармакологические подходы к противокашлевой терапии. Рус. мед. журн. 2011 (23): 1150–8.
[Okovityi S.V., Anisimova N.A. Farmakologicheskie podkhody k protivokashlevoi terapii. Rus. med. zhurn. 2011 (23): 1150–8 (in Russian).]
16. Зайцев А.А. Мукоактивная терапия кашля: что за горизонтом? Лечащий врач. 2018; 10: 22–6.
[Zaitsev A.A. Mukoaktivnaia terapiia kashlia: chto za gorizontom? Lechashchii vrach. 2018; 10: 22–6 (in Russian).]
17. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2011; 322 (7297).
18. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005; 25 (3): 552–63.
19. Ekberg-Jansson A, Larsson S, Lofdahl C-G. Preventing exacerbations of chronic bronchitis and COPD. Two recent Cochrane reviews report effective regimens. BMJ 2001; 322: 7297.
20. Beeh KM, Beier J, Esperester A, Paul LD. Antiinflammatory properties of ambroxol. Eur J Med Res 2008; 13: 12: 557–62.
21. Балясинская Г.Л., Богомильский М.Р., Люманова С.Р., Волков И.К. Применение Флуимуцила (N-ацетилцистеина) при заболеваниях легких. Педиатрия. 2005; 6.
[Baliasinskaia G.L., Bogomil'skii M.R., Liumanova S.R., Volkov I.K. Primenenie Fluimutsila (N-atsetiltsisteina) pri zabolevaniiakh legkikh. Pediatriia. 2005; 6 (in Russian).]
22. Cazzola M, Calzetta L, Page C et al. Influence of Nacetylcysteine on chronic bronchitis or COPD exacerbations: a metaanalysis. Eur Respir Rev 2015; 24 (137): 451–61.
23. Stey C et al. The effect of oral N-Acetylcysteine in chronic bronchitis: a guantitative systematic review. Eur Respir J 2000; 16: 253–62.
________________________________________________
2. Chuchalin A.G., Ambrosimov V.N. Kashel'. M.: Ekho, 2012 (in Russian).
3. Morice A. Epidemiology of cough. Pulm Pharmacol Ther 2002; 15: 253–9.
4. Burt CW, Schappert SM. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1999–2000. Vital Health Stat 2004; 157: 1–70.
5. Cerveri I, Accordini S, Corsico A et al. Chronic cough and phlegm in young adults. Eur Respir J 2003; 22 (3): 413–7.
6. Cullinan P. Persistent cough and sputum: prevalence and clinical characteristics in south east England. Respir Med 1992; 86: 143–9.
7. Lundback B, Nystrom L, Rosenhall L et al. Obstructive lung disease in northern Sweden: respiratory symptoms assessed in a postal survey. Eur Respir J 1991; 4: 257–66.
8. Cough. Understanding and treating a problem with many causes. Am College Chest Physicians 2000.
9. Berdnikova N.G., Tsyganko D.V., Demidova G.V. Osobennosti primeneniia atsetiltsisteina v klinicheskoi praktike. RMZh. 2008; 16 (2): 78–82 (in Russian).
10. Lindner Н, Holier Е, Erd В. Peripheral blood mononuclear cells induce programmed cell death in human endothelial cells and mav prevent repair: role of cytokines. Blood 1997; 89 (6): 1931–8.
11. Votchal B.E. Ocherki klinicheskoi farmakologii. M., 1965; s. 428–33 (in Russian).
12. Reznikov A.M., Marchenkov Ia.V. Khronicheskii persistiruiushchii kashel'. Atmosfera. Pul'monologiia i allergologiia. 2002; 4: 40–1 (in Russian).
13. Zaitsev A.A., Okovityi S.V., Kriukov E.V. Kashel'. Prakticheskoe posobie dlia vrachei. Мoscow, 2015 (in Russian).
14. Albert RH. Diagnosis and treatment of acute bronchitis. Am Fam Physician 2010; 82: 1345–50.
15. Okovityi S.V., Anisimova N.A. Farmakologicheskie podkhody k protivokashlevoi terapii. Rus. med. zhurn. 2011 (23): 1150–8 (in Russian).
16. Zaitsev A.A. Mukoaktivnaia terapiia kashlia: chto za gorizontom? Lechashchii vrach. 2018; 10: 22–6 (in Russian).
17. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2011; 322 (7297).
18. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005; 25 (3): 552–63.
19. Ekberg-Jansson A, Larsson S, Lofdahl C-G. Preventing exacerbations of chronic bronchitis and COPD. Two recent Cochrane reviews report effective regimens. BMJ 2001; 322: 7297.
20. Beeh KM, Beier J, Esperester A, Paul LD. Antiinflammatory properties of ambroxol. Eur J Med Res 2008; 13: 12: 557–62.
21. Baliasinskaia G.L., Bogomil'skii M.R., Liumanova S.R., Volkov I.K. Primenenie Fluimutsila (N-atsetiltsisteina) pri zabolevaniiakh legkikh. Pediatriia. 2005; 6 (in Russian).
22. Cazzola M, Calzetta L, Page C et al. Influence of Nacetylcysteine on chronic bronchitis or COPD exacerbations: a metaanalysis. Eur Respir Rev 2015; 24 (137): 451–61.
23. Stey C et al. The effect of oral N-Acetylcysteine in chronic bronchitis: a guantitative systematic review. Eur Respir J 2000; 16: 253–62.
Авторы
А.Н. Кучмин, К.Б. Евсюков, С.Н. Шуленин, А.А. Шевелев
ФГБВОУ ВО «Военно-медицинская академия им. С.М. Кирова» Минобороны России, Санкт-Петербург, Россия
*konsta54@yandex.ru
Kirov Military Medical Academy, Saint Petersburg, Russia
*konsta54@yandex.ru
ФГБВОУ ВО «Военно-медицинская академия им. С.М. Кирова» Минобороны России, Санкт-Петербург, Россия
*konsta54@yandex.ru
________________________________________________
Kirov Military Medical Academy, Saint Petersburg, Russia
*konsta54@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.